Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study - PubMed
6 hours ago
- #PCNSL
- #Lenalidomide
- #BTK inhibitors
- BTK inhibitors (BTKi) showed superior progression-free survival (PFS) compared to lenalidomide in primary CNS lymphoma (PCNSL) maintenance therapy.
- The 6-year PFS rate was significantly higher with BTKi (91.3%) than with lenalidomide (41.5%).
- BTKi benefit was consistent regardless of maintenance duration, while lenalidomide showed variability based on treatment duration.
- Overall survival (OS) was similar between both groups, despite differences in PFS.
- Most patients relapsing on lenalidomide transitioned to BTKi-based regimens, achieving a median second-line PFS of 20.5 months.
- No treatment-related deaths occurred in the study.
- The study suggests BTKi as a highly effective first-line maintenance strategy for PCNSL, pending further prospective trials.